| Jeness L Woodard, LCSW | |
|
145 W University Pkwy, Orem, UT 84058-7316 | |
| (801) 234-8600 | |
| Not Available |
| Full Name | Jeness L Woodard |
|---|---|
| Gender | Female |
| Speciality | Social Worker - Clinical |
| Location | 145 W University Pkwy, Orem, Utah |
| Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1881031771 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 1041C0700X | Social Worker - Clinical | 79455973501 (Utah) | Primary |
| Entity Name | Trauma Awareness & Treatment Center Inc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1770542219 PECOS PAC ID: 8325078306 Enrollment ID: O20050818001076 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists have determined that decay-accelerating factor (DAF), a protein found in epithelial cells in the stomach, acts as a receptor for the bacteria Helicobacter pylori. Blocking this interaction could lead to new drugs that reduce the risk of peptic ulcer disease or gastric cancer.
Researchers at UPMC Hillman Cancer Center and the National Cancer Institute demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy-;which has a failure rate of 40% for this type of cancer-;into patients who do.
Research carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI), recently published in the journal Family Practice aims to help patients that have suffered a transient ischaemic attack (TIA), otherwise known as a "mini-stroke" by assessing their risk of subsequent stroke.
Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.
› Verified 2 days ago
| Entity Name | University Of Utah Behavioral Health Services |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1740688613 PECOS PAC ID: 9537483607 Enrollment ID: O20150120001118 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists have determined that decay-accelerating factor (DAF), a protein found in epithelial cells in the stomach, acts as a receptor for the bacteria Helicobacter pylori. Blocking this interaction could lead to new drugs that reduce the risk of peptic ulcer disease or gastric cancer.
Researchers at UPMC Hillman Cancer Center and the National Cancer Institute demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy-;which has a failure rate of 40% for this type of cancer-;into patients who do.
Research carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI), recently published in the journal Family Practice aims to help patients that have suffered a transient ischaemic attack (TIA), otherwise known as a "mini-stroke" by assessing their risk of subsequent stroke.
Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.
› Verified 2 days ago
| Entity Name | University Of Utah Community Physicians Group |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1598169203 PECOS PAC ID: 9739403569 Enrollment ID: O20150126002118 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists have determined that decay-accelerating factor (DAF), a protein found in epithelial cells in the stomach, acts as a receptor for the bacteria Helicobacter pylori. Blocking this interaction could lead to new drugs that reduce the risk of peptic ulcer disease or gastric cancer.
Researchers at UPMC Hillman Cancer Center and the National Cancer Institute demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy-;which has a failure rate of 40% for this type of cancer-;into patients who do.
Research carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI), recently published in the journal Family Practice aims to help patients that have suffered a transient ischaemic attack (TIA), otherwise known as a "mini-stroke" by assessing their risk of subsequent stroke.
Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.
› Verified 2 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Jeness L Woodard, LCSW 145 W University Pkwy, Orem, UT 84058-7316 Ph: (801) 234-8600 | Jeness L Woodard, LCSW 145 W University Pkwy, Orem, UT 84058-7316 Ph: (801) 234-8600 |
News Archive
Karolinska Development AB (publ), and BioChromix AB announced today the formation of BioChromix Pharma AB, a new company working to develop a novel Alzheimer treatment with its unique knowledge of molecular chemistry. Karolinska Development will initially take 28 percent ownership in the new company.
Scientists have determined that decay-accelerating factor (DAF), a protein found in epithelial cells in the stomach, acts as a receptor for the bacteria Helicobacter pylori. Blocking this interaction could lead to new drugs that reduce the risk of peptic ulcer disease or gastric cancer.
Researchers at UPMC Hillman Cancer Center and the National Cancer Institute demonstrate that changing the gut microbiome can transform patients with advanced melanoma who never responded to immunotherapy-;which has a failure rate of 40% for this type of cancer-;into patients who do.
Research carried out by the HRB Centre for Primary Care Research, based in the Royal College of Surgeons in Ireland (RCSI), recently published in the journal Family Practice aims to help patients that have suffered a transient ischaemic attack (TIA), otherwise known as a "mini-stroke" by assessing their risk of subsequent stroke.
Advaxis, Inc., a leader in developing the next generation of cancer immunotherapies, announced that the first patient has been dosed in a Phase 1/2 "window of opportunity" study being conducted by the Icahn School of Medicine at Mount Sinai. Patients diagnosed with HPV-associated head and neck cancer will receive ADXS-HPV immunotherapy during the "window" of time between initial diagnosis and minimally invasive transoral robotic surgery to remove their tumors.
› Verified 2 days ago
Katie Fishman, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 600 S Geneva Rd, Orem, UT 84059 Phone: 801-877-5300 | |
Alicia Hills, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 202 E 800 S Ste 105, Orem, UT 84058 Phone: 385-283-1032 | |
Morgan Oliphant, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1255 N 1200 W, Orem, UT 84057 Phone: 801-229-1181 | |
Rebecca Jane Mcnairy, Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1125 W Center St, Orem, UT 84057 Phone: 801-903-5903 | |
Erin Elizabeth Vasquez, LCSW, RPT Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 1255 N 1200 W, Orem, UT 84057 Phone: 801-229-1181 Fax: 801-229-2787 | |
Mr. Mark James Capell, LCSW Clinical Social Worker Medicare: Not Enrolled in Medicare Practice Location: 313 E 1200 S, Suite 104, Orem, UT 84058 Phone: 801-377-1595 Fax: 801-377-1598 | |
Terry R Routt, LCSW Clinical Social Worker Medicare: Medicare Enrolled Practice Location: 570 E 1400 S, Orem, UT 84097 Phone: 801-426-6661 Fax: 801-426-6660 |